Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Aug 2014

Innocenti Federico, Schilsky Richard L, Ramírez Jacqueline, Janisch Linda, Undevia Samir, House Larry K, Das Soma, Wu Kehua, Turcich Michelle, Marsh Robert, Karrison Theodore, Maitland Michael L, Salgia Ravi, Ratain Mark J

Abstract excerpt

PURPOSE: The risk of severe neutropenia from treatment with irinotecan is related in part to UGT1A1*28, a variant that reduces the elimination of SN-38, the active metabolite of irinotecan. We aimed to identify the maximum-tolerated dose (MTD) and dose-limiting toxicity (DLT) of irinotecan in patients with advanced solid tumors stratified by the *1/*1, *1/*28, and *28/*28 genotypes. PATIENTS AND METHODS:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Agents, Phytogenic

Share to Camptothecin

Share to Dose-Response Relationship, Drug

Share to Glucuronosyltransferase

Share to Irinotecan

Share to Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 24958824
DOI: 10.1200/JCO.2014.55.2307
PMCID: PMC4105486

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer.PMID 24958824Read ↗

Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer.Semantic proximity Read ↗

UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters.Semantic proximity Read ↗

UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine.Semantic proximity Read ↗

Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms.Semantic proximity Read ↗

A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer.Semantic proximity Read ↗

A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan.Semantic proximity Read ↗

Pharmacogenetics and irinotecan therapy.Semantic proximity Read ↗

Impact of the UGT1A1*28 allele on response to irinotecan: a systematic review and meta-analysis.Semantic proximity Read ↗

Elucidating the role of pharmacogenetics in irinotecan efficacy and adverse events in metastatic colorectal cancer patients.Semantic proximity Read ↗

Genotype-Guided Dosing Study of FOLFIRI plus Bevacizumab in Patients with Metastatic Colorectal Cancer.Semantic proximity Read ↗

Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping.Semantic proximity Read ↗

Pharmacogenetics of Irinotecan Disposition and Toxicity: A ReviewSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.